China Clears Mepolizumab for COPD

Why It Matters

The approval opens a sizable market for precision‑medicine COPD treatments in China and signals regulators’ growing willingness to endorse biomarker‑driven biologics, reshaping respiratory care globally.

Key Takeaways

• First monthly COPD biologic approved in China
• Targets patients with eosinophils ≥150 cells/µL
• Phase III trials cut exacerbations by ~20%
• Reduces hospital visits, lowering COPD costs
• Signals shift to precision respiratory medicine

Pulse Analysis

China faces one of the world’s largest COPD burdens, with roughly 100 million patients and mortality rates exceeding the global average. The disease’s economic toll is driven by frequent exacerbations that often require emergency care or hospitalization. Historically, treatment has relied on inhaled bronchodilators and steroids, leaving a therapeutic gap for patients who continue to flare despite optimal triple therapy. The recent approval of GSK’s mepolizumab (Nucala) marks the first monthly biologic indicated for COPD in the Chinese market, reflecting a broader shift toward targeted immunologic interventions in respiratory care.

The regulatory decision was anchored in data from the Phase III MATINEE and METREX studies, which enrolled adults with blood eosinophil counts of 150 cells/µL or higher and persistent exacerbations despite inhaled triple therapy. Both trials met their primary endpoints, delivering annualized exacerbation rate ratios of 0.79 and 0.82 respectively—approximately a 20 % reduction versus placebo. Importantly, the MATINEE cohort also showed fewer hospitalizations and emergency‑department visits, outcomes that dominate COPD‑related spending. Safety signals were comparable to placebo, reinforcing confidence in long‑term use of an anti‑IL‑5 monoclonal antibody for a chronic lung disease.

Beyond the immediate clinical benefit, Nucala’s clearance signals a new regulatory appetite for biomarker‑driven biologics in China’s respiratory space. With roughly two‑thirds of uncontrolled COPD patients exhibiting eosinophil levels above the 150 cells/µL threshold, the addressable market could exceed tens of millions of doses annually, prompting competitors to prioritize similar IL‑5 or IL‑4/13 pathways. Payers are likely to evaluate cost‑effectiveness models that factor in reduced hospital admissions, potentially accelerating reimbursement pathways. In the longer term, the approval may pave the way for additional biologic classes—such as anti‑TSLP or anti‑IL‑33 agents—to enter Chinese COPD guidelines, reshaping treatment algorithms worldwide.